Effect of the incretin mimetic liraglutide (Victoza) on body weight and glycated hemoglobin levels in patients with type 2 diabetes mellitus in diabetology offices in Czech Republic: the BIVI study
Abstract
The BIVI study is an observational study investigating the effect of treatment with the incretin mimetic liraglutide on body weight and type 2 diabetes (HbA1c) control in diabetology offices in the Czech Republic. During a two-year period, 21 diabetologists gathered basic data on patients who had agreed to the addition of liraglutide to the pre-existing antidiabetic treatment.
The total number of patients with T2DM who completed at least three months of continuous treatment with liraglutide was 310. The largest reduction in BMI as well as HbA1c occurred in the first six months of treatment with liraglutide (Victoza): the BMI and HbA1c decreased by 1.95 (from 38.6 kg/m2 to 36.75 kg/m2) and 1.20 % (from 7.18 % to 5.98 %), respectively.
There was also a significant improvement in waist circumference. Treatment with liraglutide was not accompanied by any significant adverse event; during months three to nine, 38 patients discontinued their treatment with liraglutide due to nausea, inefficacy, or a too high copayment.